MediciNova, Inc.(MNOV)Earnings, Financials & Key Ratios
MNOV•NASDAQ
$1.45
$71M mkt cap·Price updated May 6, 2026
AboutMediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.Show more
- Revenue$410K
- EBITDA-$13M-5.0%
- Net Income-$12M-8.6%
- EPS (Diluted)-0.24-4.3%
- Gross Margin7.58%
- EBITDA Margin-3242.47%
- Operating Margin-3242.47%
- Net Margin-2928.78%
- ROE-25.5%-32.6%
- ROIC-85.47%-7.6%
- Debt/Equity0.00+26.6%
MNOV Key Insights
MediciNova, Inc. (MNOV) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MNOV Price & Volume
MediciNova, Inc. (MNOV) stock price & volume — 10-year historical chart
Loading chart...
MNOV Growth Metrics
MediciNova, Inc. (MNOV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-8.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-6.48%
Return on Capital
10 Years-22.3%
5 Years-19.29%
3 Years-21.57%
Last Year-28.05%
MNOV Peer Comparison
MediciNova, Inc. (MNOV) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SIGA | 336.57M | 4.70 | 14.24 | -31.8% | 24.64% | 0% | 0 | |
 NRXP | 84.43M | 3.05 | -2.28 | -157.28% | ||||
 AVXL | 309.52M | 3.34 | -6.19 | -31.55% | ||||
 ATHA | 17.12M | 4.34 | -0.17 | -340.97% | 0.03 | |||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 SUPN | 2.96B | 51.45 | -75.66 | 8.63% | -3.74% | -2.73% | 0.04 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 |
Compare MNOV vs Peers
MediciNova, Inc. (MNOV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MNOV Income Statement
MediciNova, Inc. (MNOV) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 4.04M | 0 | 1M | 0 | 409.66K |
| Revenue Growth % | - | - | - | - | - | -100% | - | -100% | - |
| Cost of Goods Sold | 28.1K | 25.88K | 23.94K | 0 | 0 | 0 | 0 | 0 | 378.61K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | 92.42% |
| Gross Profit | -28.1K▲ 0% | -25.88K▲ 7.9% | -23.94K▲ 7.5% | 0▲ 100.0% | 4.04M▲ 0% | 0▼ 100.0% | 1M▲ 0% | 0▼ 100.0% | 31.05K▲ 0% |
| Gross Margin % | - | - | - | - | 100% | - | 100% | - | 7.58% |
| Gross Profit Growth % | -98.9% | 7.89% | 7.48% | 100% | - | -100% | - | -100% | - |
| Operating Expenses | 13.03M | 15.59M | 14.03M | 14.18M | 14.25M | 14.63M | 10.9M | 12.68M | 13.31M |
| OpEx % of Revenue | - | - | - | - | 353.02% | - | 1090.03% | - | 3250.05% |
| Selling, General & Admin | 8.8M | 9.96M | 7.95M | 6.69M | 5.72M | 5.48M | 5.24M | 5.48M | 6.16M |
| SG&A % of Revenue | - | - | - | - | 141.56% | - | 524.24% | - | 1503.5% |
| Research & Development | 4.22M | 5.63M | 6.08M | 7.49M | 8.1M | 9.14M | 5.66M | 7.2M | 7.15M |
| R&D % of Revenue | - | - | - | - | 200.62% | - | 565.83% | - | 1746.55% |
| Other Operating Expenses | 120.2K | -22.89K | -46.16K | -357 | 438K | 388 | -400 | -413 | 0 |
| Operating Income | -13.03M▲ 0% | -15.59M▼ 19.6% | -14.03M▲ 10.0% | -14.18M▼ 1.0% | -10.22M▲ 27.9% | -14.63M▼ 43.2% | -9.9M▲ 32.3% | -12.68M▼ 28.0% | -13.28M▼ 4.8% |
| Operating Margin % | - | - | - | - | -253.02% | - | -990.03% | - | -3242.47% |
| Operating Income Growth % | -19.71% | -19.65% | 9.98% | -1.05% | 27.95% | -43.2% | 32.32% | -28.03% | -4.79% |
| EBITDA | -13M | -15.56M | -14.01M | -14.16M | -10.19M | -14.61M | -9.88M | -12.65M | -13.28M |
| EBITDA Margin % | - | - | - | - | -252.38% | - | -988% | - | -3242.47% |
| EBITDA Growth % | -19.61% | -19.71% | 9.99% | -1.07% | 28.02% | -43.39% | 32.38% | -28.08% | -4.97% |
| D&A (Non-Cash Add-back) | 28.1K | 25.88K | 23.94K | 21.34K | 26.15K | 17.71K | 20.3K | 21.08K | 0 |
| EBIT | -12.91M | -15.59M | -14.03M | -14.18M | -10.22M | -14.63M | -9.9M | -12.68M | -13.28M |
| Net Interest Income | 0 | 0 | 1.15M | 361.18K | 143.63K | 809.67K | 1.83M | 1.67M | 1.3M |
| Interest Income | 0 | 939.91K | 1.15M | 361.18K | 143.63K | 809.67K | 1.83M | 1.67M | 1.3M |
| Interest Expense | 298 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 119.91K | 917.01K | 1.1M | 322.78K | 84.13K | 562.39K | 1.33M | 1.63M | 1.29M |
| Pretax Income | -12.91M▲ 0% | -14.67M▼ 13.7% | -12.93M▲ 11.9% | -13.86M▼ 7.2% | -10.13M▲ 26.9% | -14.07M▼ 38.8% | -8.57M▲ 39.1% | -11.04M▼ 28.9% | -11.99M▼ 8.6% |
| Pretax Margin % | - | - | - | - | -250.94% | - | -856.85% | - | -2927.32% |
| Income Tax | -1.74M | 5.28K | 12.66K | -1.65K | 2.57K | 2.82K | 3.05K | 5.54K | 5.99K |
| Effective Tax Rate % | 13.51% | -0.04% | -0.1% | 0.01% | -0.03% | -0.02% | -0.04% | -0.05% | -0.05% |
| Net Income | -11.16M▲ 0% | -14.68M▼ 31.5% | -12.94M▲ 11.8% | -13.85M▼ 7.0% | -10.13M▲ 26.8% | -14.07M▼ 38.8% | -8.57M▲ 39.1% | -11.05M▼ 28.9% | -12M▼ 8.6% |
| Net Margin % | - | - | - | - | -251% | - | -857.15% | - | -2928.78% |
| Net Income Growth % | -2.73% | -31.46% | 11.81% | -7.05% | 26.85% | -38.83% | 39.08% | -28.91% | -8.58% |
| Net Income (Continuing) | -11.16M | -14.68M | -12.94M | -13.85M | -10.13M | -14.07M | -8.57M | -11.05M | -12M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.32▲ 0% | -0.36▼ 12.5% | -0.30▲ 16.7% | -0.31▼ 3.3% | -0.21▲ 32.3% | -0.29▼ 38.1% | -0.17▲ 41.4% | -0.23▼ 35.3% | -0.24▼ 4.3% |
| EPS Growth % | 3.03% | -12.5% | 16.67% | -3.33% | 32.26% | -38.1% | 41.38% | -35.29% | -4.35% |
| EPS (Basic) | -0.32 | -0.36 | -0.30 | -0.31 | -0.21 | -0.29 | -0.17 | -0.23 | -0.24 |
| Diluted Shares Outstanding | 35.14M | 41.12M | 43.16M | 44.41M | 48.6M | 49.05M | 49.05M | 49.05M | 49.06M |
| Basic Shares Outstanding | 35.14M | 41.12M | 43.16M | 44.41M | 48.6M | 49.05M | 49.05M | 49.05M | 49.06M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
MNOV Balance Sheet
MediciNova, Inc. (MNOV) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 28.33M | 62.76M | 64.3M | 60.72M | 72.01M | 58.99M | 51.17M | 41.07M | 30.99M |
| Cash & Short-Term Investments | 27.99M | 62.31M | 63.79M | 60.04M | 71.43M | 58.49M | 51M | 40.36M | 30.81M |
| Cash Only | 27.99M | 62.31M | 63.79M | 60.04M | 71.43M | 18.51M | 51M | 40.36M | 30.81M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 39.98M | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 511.92K | 0 | 0 | 0 | 174.94K | 714.54K | 184.83K |
| Total Non-Current Assets | 15.09M | 14.46M | 14.9M | 14.7M | 15.4M | 15.17M | 15.1M | 14.8M | 14.61M |
| Property, Plant & Equipment | 62.89K | 53.13K | 40.55K | 226.56K | 881.78K | 674.76K | 621.21K | 382.41K | 192.57K |
| Fixed Asset Turnover | - | - | - | - | 4.58x | - | 1.61x | - | 2.13x |
| Goodwill | 9.6M | 9.6M | 9.6M | 9.6M | 9.6M | 9.6M | 9.6M | 9.6M | 9.6M |
| Intangible Assets | 4.8M | 4.8M | 4.8M | 4.8M | 4.8M | 4.8M | 4.8M | 4.8M | 0 |
| Long-Term Investments | 616.66K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 10.96K | 10.96K | 459.81K | 75.38K | 115.49K | 92.79K | 74.15K | 19K | 4.82M |
| Total Assets | 43.42M▲ 0% | 77.22M▲ 77.9% | 79.21M▲ 2.6% | 75.42M▼ 4.8% | 87.41M▲ 15.9% | 74.15M▼ 15.2% | 66.27M▼ 10.6% | 55.88M▼ 15.7% | 45.6M▼ 18.4% |
| Asset Turnover | - | - | - | - | 0.05x | - | 0.02x | - | 0.01x |
| Asset Growth % | 9.06% | 77.85% | 2.57% | -4.78% | 15.89% | -15.16% | -10.63% | -15.68% | -18.39% |
| Total Current Liabilities | 2.88M | 2.19M | 2.23M | 2.19M | 2.83M | 3.19M | 3.28M | 2.96M | 3.8M |
| Accounts Payable | 1.52M | 616.75K | 451.33K | 616.63K | 402.74K | 424.65K | 1M | 1.1M | 625K |
| Days Payables Outstanding | 19.75K | 8.7K | 6.88K | - | - | - | - | - | 602.53 |
| Short-Term Debt | 0 | 0 | 216.77K | 0 | 0 | 0 | 0 | 0 | 194.33K |
| Deferred Revenue (Current) | 1.69B | 1.69B | 0 | 0 | 0 | 0 | 0 | 0 | 370.16K |
| Other Current Liabilities | 0 | 191.93K | 791.65K | 924.3K | 547.27K | 184.1K | 988.76K | 912.78K | 2.61M |
| Current Ratio | 9.83x | 28.63x | 28.86x | 27.67x | 25.42x | 18.51x | 15.61x | 13.88x | 8.16x |
| Quick Ratio | 9.83x | 28.63x | 28.86x | 27.67x | 25.42x | 18.51x | 15.61x | 13.88x | 8.16x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.9M | 1.92M | 2.08M | 1.9M | 896.47K | 725.41K | 612.45K | 413.25K | 218.92K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 182.58K | 0 | 694.67K | 523.62K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 201.79K | 201.79K | 201.79K | 201.79K | 0 | 0 | 201.79K | 201.79K | 201.79K |
| Other Non-Current Liabilities | 0 | 27.21K | 3.78K | 2.71K | 201.79K | 201.79K | 410.66K | 211.46K | 17.13K |
| Total Liabilities | 4.78M | 4.12M | 4.31M | 4.09M | 3.73M | 3.91M | 3.89M | 3.37M | 4.02M |
| Total Debt | 0 | 27.21M | 399.35K | 186.03K | 826.64K | 681.12K | 215.93K | 193.77K | 194.33K |
| Net Debt | -27.99M | -35.1M | -63.39M | -59.85M | -70.6M | -17.82M | -50.78M | -40.17M | -30.61M |
| Debt / Equity | - | 0.37x | 0.01x | 0.00x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -43715.08x | - | - | - | - | - | - | - | - |
| Total Equity | 38.64M▲ 0% | 73.11M▲ 89.2% | 74.89M▲ 2.4% | 71.33M▼ 4.8% | 83.68M▲ 17.3% | 70.24M▼ 16.1% | 62.38M▼ 11.2% | 52.5M▼ 15.8% | 41.59M▼ 20.8% |
| Equity Growth % | 11.9% | 89.19% | 2.44% | -4.76% | 17.32% | -16.06% | -11.2% | -15.83% | -20.79% |
| Book Value per Share | 1.10 | 1.78 | 1.74 | 1.61 | 1.72 | 1.43 | 1.27 | 1.07 | 0.85 |
| Total Shareholders' Equity | 38.64M | 73.11M | 74.89M | 71.33M | 83.68M | 70.24M | 62.38M | 52.5M | 41.59M |
| Common Stock | 36.45K | 42.08K | 43.91K | 45.02K | 49.04K | 49.05K | 49.05K | 49.05K | 49.22K |
| Retained Earnings | -341.46M | -356.13M | -369.07M | -382.93M | -393.06M | -407.13M | -415.7M | -426.75M | -438.75M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -94.62K | -93.15K | -92.68K | -88.22K | -98.88K | -115.28K | -118.09K | -135.15K | -127.18K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MNOV Cash Flow Statement
MediciNova, Inc. (MNOV) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -6.92M | -9.11M | -9.12M | -10.83M | -9.38M | -12.91M | -7.43M | -10.64M | -9.81M |
| Operating CF Margin % | - | - | - | - | -232.36% | - | -743.1% | - | -2394.7% |
| Operating CF Growth % | -5.77% | -31.63% | -0.12% | -18.65% | 13.34% | -37.63% | 42.45% | -43.22% | 7.83% |
| Net Income | -11.16M | -14.68M | -12.94M | -13.85M | -10.13M | -14.07M | -8.57M | -11.05M | -12M |
| Depreciation & Amortization | 28.1K | 25.88K | 23.94K | 21.34K | 26.15K | 17.71K | 20.3K | 21.08K | 20.1K |
| Stock-Based Compensation | 4.47M | 6.33M | 4.11M | 3.18M | 1.72M | 642.52K | 710.71K | 1.19M | 829.1K |
| Deferred Taxes | -1.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.9M | -19.87K | 0 | 210.21K | 216.93K | 163.19K | 297.49K | 173.32K | 878.83K |
| Working Capital Changes | -265.51K | -775.35K | -319.92K | -379.57K | -1.21M | 334.1K | 111.99K | -979.56K | 459.87K |
| Change in Receivables | 242.06K | -111.68K | -514.02K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.25M | -663.67K | 194.1K | -4.77K | -1.03M | 329.01K | 19.24K | -312.35K | 459.87K |
| Cash from Investing | -84.48M | 626.32K | -11.27K | -36.49K | -28.73K | -40.01M | 39.91M | -697 | -2.9K |
| Capital Expenditures | 0 | -10.2K | -11.27K | -36.49K | -28.73K | -5.01K | -21.3K | -895 | 0 |
| CapEx % of Revenue | - | - | - | - | 0.71% | - | 2.13% | - | - |
| Acquisitions | 0 | 636.52K | 0 | 0 | 0 | 5.01M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -84.48M | 636.52K | 0 | 0 | 0 | -5.01M | 0 | 198 | -2.9K |
| Cash from Financing | 10.8M | 42.81M | 10.62M | 7.11M | 20.78M | 7.92K | 0 | 0 | 244.02K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 7.92K | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 77.32K | 51.01K | -261.05K | -192.13K | -112.26K | 0 | 0 | 0 | 244.02K |
| Net Change in Cash | 3.87M▲ 0% | 34.32M▲ 786.0% | 1.48M▼ 95.7% | -3.76M▼ 353.9% | 11.39M▲ 403.4% | -52.93M▼ 564.5% | 32.49M▲ 161.4% | -10.64M▼ 132.7% | -9.55M▲ 10.2% |
| Free Cash Flow | -6.92M▲ 0% | -9.12M▼ 31.8% | -9.14M▼ 0.1% | -10.86M▼ 18.9% | -9.41M▲ 13.4% | -12.92M▼ 37.3% | -7.45M▲ 42.3% | -10.64M▼ 42.8% | -9.81M▲ 7.8% |
| FCF Margin % | - | - | - | - | -233.07% | - | -745.23% | - | -2394.7% |
| FCF Growth % | -4.42% | -31.78% | -0.13% | -18.9% | 13.37% | -37.26% | 42.3% | -42.83% | 7.83% |
| FCF per Share | -0.20 | -0.22 | -0.21 | -0.24 | -0.19 | -0.26 | -0.15 | -0.22 | -0.20 |
| FCF Conversion (FCF/Net Income) | 0.62x | 0.62x | 0.71x | 0.78x | 0.93x | 0.92x | 0.87x | 0.96x | 0.82x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 9.2K | 6K | 11.27K | 1.49K | 0 | 0 | 3.67K | 5.04K | 0 |
MNOV Key Ratios
MediciNova, Inc. (MNOV) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -32.3% | -30.51% | -26.26% | -17.49% | -18.95% | -13.08% | -18.28% | -12.93% | -19.24% | -25.5% |
| Return on Invested Capital (ROIC) | -46.99% | -88.69% | -48.05% | -42.51% | -92.56% | -62.42% | -33.51% | -23.2% | -79.44% | -85.47% |
| Gross Margin | - | - | - | - | - | 100% | - | 100% | - | 7.58% |
| Net Margin | - | - | - | - | - | -251% | - | -857.15% | - | -2928.78% |
| Debt / Equity | 0.03x | - | 0.37x | 0.01x | 0.00x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x |
| Interest Coverage | -23968.80x | -43715.08x | - | - | - | - | - | - | - | - |
| FCF Conversion | 0.60x | 0.62x | 0.62x | 0.71x | 0.78x | 0.93x | 0.92x | 0.87x | 0.96x | 0.82x |
| Revenue Growth | - | - | - | - | - | - | -100% | - | -100% | - |
MNOV Frequently Asked Questions
MediciNova, Inc. (MNOV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
MediciNova, Inc. (MNOV) reported $0.4M in revenue for fiscal year 2025.
MediciNova, Inc. (MNOV) grew revenue by 0.0% over the past year. Growth has been modest.
MediciNova, Inc. (MNOV) reported a net loss of $12.0M for fiscal year 2025.
Dividend & Returns
MediciNova, Inc. (MNOV) has a return on equity (ROE) of -25.5%. Negative ROE indicates the company is unprofitable.
MediciNova, Inc. (MNOV) had negative free cash flow of $9.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More MNOV
MediciNova, Inc. (MNOV) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates